DPDoctor's PassportEducation
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
RapidMLAMSRAGP

Vision screening and refractive error in children

Essential points for quick revision.

!
Symptoms override a previous screening pass

A screening result is not a lifelong guarantee of eye health. A white pupil, acute visual loss, painful red eye or new neurological features requires assessment outside the routine screening pathway.

Action: Use the appropriate urgent eye or paediatric service for red flags. Do not ask a symptomatic child to wait for the next school screening session or routine sight test.

Synopsis

Apply the childhood vision-screening pathway, interpret monocular acuity correctly and arrange a complete assessment of refractive error and visual development.

  • The UK NSC recommends vision screening at four to five years.
  • England's programme uses an orthoptist-led service and the Keeler Crowded logMAR test.
  • Test each eye separately with effective occlusion and the child's prescribed correction.

Key red flags

A white, absent or clearly asymmetric red reflex.

Investigation priorities

01
Keeler Crowded logMAR screeningFirst step

Identify reduced monocular acuity in the eligible screening population.

Management branches

Population screeningOffer and perform an accessible test

A child is eligible for the four-to-five-year vision-screening programme.

  1. Confirm the child's identity, eligibility and the local consent arrangements before testing.
  2. Provide an understandable explanation and practise the matching task as necessary.
Open full textbook Answer 2 questions
Sources and review status7 sources · checked 7 Sept 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 7 Sept 2026; clinical approval remains outstanding.

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom